ANG003 Dose A
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Anagram Therapeutics, Inc.
Overview
ANG003 Dose A is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
ANG003 Dose A clinical trials
Explore related
Medical disclaimer. This page summarizes research about ANG003 Dose A for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.